Evolution of Cell Therapies Derived from Adipose Tissue: Historical Perspectives, Current Development Trends and Future Directions
August 2025
in “
Biology Direct
”
TLDR Adipose tissue therapies have advanced from tissue to cell and cell-free treatments, showing promise but also limitations.
The document explores the evolution and potential of cell therapies derived from adipose tissue, emphasizing their regenerative, anti-inflammatory, and pro-angiogenic properties. Adipose-derived stromal cells (ADSCs) and the stromal vascular fraction (SVF) are highlighted for their ability to differentiate, low immunogenicity, and immunosuppressive properties, making them effective in reducing inflammation, promoting tissue repair, and exhibiting anti-fibrotic effects. Despite challenges in isolating ADSCs, their clinical use has shown safety and efficacy, particularly in enhancing fat grafting and treating conditions like Crohn's disease. The document also notes the shift towards cell-free grafting for more precise reconstruction, although standardized procedures for ADSC application are still needed to improve result comparison across studies.
